A Systematic Review of the Utility of Amino Acid PET in Assessing Treatment Response to Bevacizumab in Recurrent High-grade Glioma

Overview

Journal Neurooncol Adv

Publisher Oxford University Press

Date 2021 Aug 19

PMID 34409294

Citations 7

Authors

Kendall L Hughes

Christen M ONeal

Bethany J Andrews

Alison M Westrup

James D Battiste

Chad A Glenn

Affiliations

Soon will be listed here.

Abstract

Background: Currently, bevacizumab (BEV), an antiangiogenic agent, is used as an adjunctive therapy to re-irradiation and surgery in patients with recurrent high-grade gliomas (rHGG). BEV has shown to decrease enhancement on MRI, but it is often unclear if these changes are due to tumor response to BEV or treatment-induced changes in the blood brain barrier. Preliminary studies show that amino acid PET can aid in distinguishing these changes on MRI.

Methods: The authors performed a systematic review of PubMed and Embase through July 2020 with the search terms 'bevacizumab' or 'Avastin' and 'recurrent glioma' and 'PET,' yielding 38 papers, with 14 meeting inclusion criteria.

Results: Thirteen out of fourteen studies included in this review used static PET and three studies used dynamic PET to evaluate the use of BEV in rHGG. Six studies used the amino acid tracer [18F]FET, four studies used [11C]MET, and four studies used [18F]FDOPA.

Conclusion: [18F]FET, [11C]MET, and [18F]FDOPA PET in combination with MRI have shown promising results for improving accuracy in diagnosing tumor recurrence, detecting early treatment failure, and distinguishing between tumor progression and treatment-induced changes in patients with rHGG treated with BEV.

Citing Articles

Magnetic resonance imaging and o-(2-[F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma.

Henriksen O, Maarup S, Hasselbalch B, Poulsen H, Christensen I, Madsen K Neurooncol Adv. 2024; 6(1):vdae178.

PMID: 39659835 PMC: 11630048. DOI: 10.1093/noajnl/vdae178.

Hybrid Positron Emission Tomography and Magnetic Resonance Imaging Guided Microsurgical Management of Glial Tumors: Case Series and Review of the Literature.

Caglar Y, Buyuktepe M, Sayaci E, Dogan I, Bozkurt M, Peker E Diagnostics (Basel). 2024; 14(14).

PMID: 39061688 PMC: 11275485. DOI: 10.3390/diagnostics14141551.

Amino acid PET vs. RANO MRI for prediction of overall survival in patients with recurrent high grade glioma under bevacizumab therapy.

Chaban A, Waschulzik B, Bernhardt D, Delbridge C, Schmidt-Graf F, Wagner A Eur J Nucl Med Mol Imaging. 2024; 51(6):1698-1702.

PMID: 38228970 PMC: 11043199. DOI: 10.1007/s00259-024-06601-4.

F-Fluoroethyl-L Tyrosine Positron Emission Tomography Radiomics in the Differentiation of Treatment-Related Changes from Disease Progression in Patients with Glioblastoma.

Manzarbeitia-Arroba B, Hodolic M, Pichler R, Osipova O, Soriano-Castrejon A, Garcia-Vicente A Cancers (Basel). 2024; 16(1).

PMID: 38201621 PMC: 10778283. DOI: 10.3390/cancers16010195.

The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment.

Kambe A, Kitao S, Ochiai R, Hosoya T, Fujii S, Kurosaki M J Neurooncol. 2024; 166(1):175-183.

PMID: 38165552 DOI: 10.1007/s11060-023-04550-w.

References

Galldiks N, Law I, Pope W, Arbizu J, Langen K . The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin. 2017; 13:386-394. PMC: 5226808. DOI: 10.1016/j.nicl.2016.12.020. View

Wardak M, Schiepers C, Cloughesy T, Dahlbom M, Phelps M, Huang S . ¹⁸F-FLT and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2014; 41(6):1199-209. PMC: 4008691. DOI: 10.1007/s00259-013-2678-2. View

Fleischmann D, Unterrainer M, Bartenstein P, Belka C, Albert N, Niyazi M . F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images?. J Neurooncol. 2017; 132(2):277-286. DOI: 10.1007/s11060-016-2366-8. View

Galldiks N, Langen K, Holy R, Pinkawa M, Stoffels G, Nolte K . Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J Nucl Med. 2012; 53(7):1048-57. DOI: 10.2967/jnumed.111.098590. View

Law I, Albert N, Arbizu J, Boellaard R, Drzezga A, Galldiks N . Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2018; 46(3):540-557. PMC: 6351513. DOI: 10.1007/s00259-018-4207-9. View

Habermeier A, Graf J, Sandhofer B, Boissel J, Roesch F, Closs E . System L amino acid transporter LAT1 accumulates O-(2-fluoroethyl)-L-tyrosine (FET). Amino Acids. 2014; 47(2):335-44. DOI: 10.1007/s00726-014-1863-3. View

Heinzel A, Muller D, Langen K, Blaum M, Verburg F, Mottaghy F . The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis. J Nucl Med. 2013; 54(8):1217-22. DOI: 10.2967/jnumed.113.120089. View

Diaz R, Ali S, Qadir M, de la Fuente M, Ivan M, Komotar R . The role of bevacizumab in the treatment of glioblastoma. J Neurooncol. 2017; 133(3):455-467. DOI: 10.1007/s11060-017-2477-x. View

George E, Kijewski M, Dubey S, Belanger A, Reardon D, Wen P . Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. AJR Am J Roentgenol. 2018; 211(6):1342-1347. DOI: 10.2214/AJR.18.19988. View

10.

Galldiks N, Rapp M, Stoffels G, Fink G, Shah N, Coenen H . Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging. 2012; 40(1):22-33. DOI: 10.1007/s00259-012-2251-4. View

11.

Garcia J, Baquero M, Bassa P, Soler M, Moragas M, Riera E . Diagnosed recurrent glioma and antiangiogenic treatment response by 11C-Methionine PET. Rev Esp Med Nucl Imagen Mol. 2015; 34(6):398-9. DOI: 10.1016/j.remn.2015.04.001. View

12.

Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11):1963-72. DOI: 10.1200/JCO.2009.26.3541. View

13.

Pauleit D, Floeth F, Hamacher K, Riemenschneider M, Reifenberger G, Muller H . O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005; 128(Pt 3):678-87. DOI: 10.1093/brain/awh399. View

14.

Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H . O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011; 52(6):856-64. DOI: 10.2967/jnumed.110.086645. View

15.

Zikou A, Sioka C, Alexiou G, Fotopoulos A, Voulgaris S, Argyropoulou M . Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2019; 2018:6828396. PMC: 6305027. DOI: 10.1155/2018/6828396. View

16.

Youland R, Kitange G, Peterson T, Pafundi D, Ramiscal J, Pokorny J . The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol. 2012; 111(1):11-8. PMC: 3907171. DOI: 10.1007/s11060-012-0986-1. View

17.

Yang D . Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria. Neurooncol Pract. 2019; 3(1):59-67. PMC: 6760341. DOI: 10.1093/nop/npv023. View

18.

Galldiks N, Langen K . Amino acid PET in neuro-oncology: applications in the clinic. Expert Rev Anticancer Ther. 2017; 17(5):395-397. DOI: 10.1080/14737140.2017.1302799. View

19.

Albert N, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim M . Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18(9):1199-208. PMC: 4999003. DOI: 10.1093/neuonc/now058. View

20.

Beppu T, Terasaki K, Sasaki T, Sato Y, Tomabechi M, Kato K . MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma. Clin Nucl Med. 2016; 41(11):852-857. DOI: 10.1097/RLU.0000000000001377. View